SynthesisMolecular neurobiology2016
Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.
Synthesis in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- The Prognostic Value of CD133 in Predicting the Relapse and Recurrence Pattern of High-Grade Gliomas on MRI: A Meta-Analysis.Frontiers in oncology · 2021Pooled it
- CD147 and glioma: a meta-analysis.Journal of neuro-oncology · 2017Pooled it
- Nestin Expression Is Associated with Poor Clinicopathological Features and Prognosis in Glioma Patients: an Association Study and Meta-analysis.Molecular neurobiology · 2017Pooled it
- Pooled it
- Advancing glioblastoma therapy with surface-modified nanoparticles.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Tumor heterogeneity and resistance in glioblastoma: the role of stem cells.Apoptosis : an international journal on programmed cell death · 2025Review
- Article
- The Impact of Glycosylation on the Functional Activity of CD133 and the Accuracy of Its Immunodetection.Biology · 2024Review
- Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons.International journal of molecular sciences · 2023Review
- An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma.Current oncology (Toronto, Ont.) · 2023Review
- Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates.Frontiers in genetics · 2022Article
- Review
- The Role of Cancer Stem Cells in Radiation Resistance.Frontiers in oncology · 2020Review
- Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
- MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133Journal of molecular neuroscience : MN · 2018Article
- The role of CD133 in cancer: a concise review.Clinical and translational medicine · 2018Review
- CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma.Molecules and cells · 2017Article
- Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation.Oncotarget · 2017Article
- CD133 in brain tumor: the prognostic factor.Oncotarget · 2017Article
- CD133 and BMI1 expressions and its prognostic role in primary glioblastoma.Journal of genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, CD133 has been identified as a cancer stem cell (CSC) marker in gliomas. Nevertheless, the clinical and prognostic value of CD133 in glioma patients remains controversial. Therefore, we conducted a systematic meta-analysis to evaluate the correlation of CD133 with World Health Organization (WHO) grade, age, gender, overall survival (OS), and progression-free survival (PFS) in glioma patients. Eligible studies on this subject were included, and then pooled odd ratios (ORs) and hazard ratios (HRs) with 95 % confidence intervals (95 % CIs) were estimated. Publication bias was assessed by the funnel plots, and heterogeneity and sensitivity were analyzed as well. In the present study, 21 articles with the total number of 1535 patients were included. High expression of CD133 in glioma patients was associated with high WHO grade (III + IV) (n = 11, OR 5.10, 95 % CI 2.99-8.69; p = 0.000), rather than age (n = 4, OR 2.54, 95 % CI 0.68-9.52; p = 0.167) and gender (n = 4, OR 0.71, 95 % CI 0.21-2.45; p = 0.587). In addition, survival analysis demonstrated a significant association between CD133 high expression and poor 2-year OS (n = 11, HR 2.18, 95 % CI 1.29-3.7; p = 0.004), 5-year OS (n = 4, HR 10.39, 95 % CI 2.59-41.63; p = 0.001), as well as PFS (n = 10, HR 2.34, 95 % CI 1.62-3.37; p = 0.000). Taken together, this study suggests that CD133 expression correlates to higher grade of gliomas and worse prognosis in glioma patients. Thus, CD133 could be recommended as a useful pathological and prognostic biomarker in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.